GlassScriptPhysician profile
Vincent A Rella
NPI 1801837711
$8,972.56
in general payments reported to CMS, 2019-2025
51 companies · $50.65 in 2025
The $50.65 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $362 · 2021: $86.13 · 2022: $633 · 2023: $2,819 · 2024: $3,341 · 2025: $50.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,800 · Education: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,799.92 |
| Education | $410.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $698.01 | 2019-2024 | |
| Janssen Biotech, INC. | $603.90 | 2019-2024 | Erleada, Darzalex, Akeega |
| Celgene Corporation | $531.35 | 2019-2024 | Pomalyst, Reblozyl, Opdualag |
| Abbvie INC. | $494.55 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $492.67 | 2019-2024 | Enhertu, Tagrisso, Calquence |
| E.R. Squibb & Sons, L.L.C. | $438.83 | 2019-2024 | Opdivo, Krazati, Opdualag |
| Gilead Sciences, INC. | $416.41 | 2019-2024 | Trodelvy |
| Genentech USA, INC. | $398.91 | 2019-2024 | Venclexta, Tecentriq, Phesgo |
| Pharmacyclics LLC, An Abbvie Company | $316.48 | 2019-2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $279.15 | 2019-2024 | |
| Mirati Therapeutics, INC. | $272.38 | 2023-2024 | Krazati |
| Merck Sharp & Dohme LLC | $263.28 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Sanofi-Aventis U.S. LLC | $236.77 | 2019-2020 | |
| Seagen INC. | $214.91 | 2019-2023 | Tukysa, Adcetris |
| Jazz Pharmaceuticals INC. | $208.42 | 2019-2024 | Zepzelca |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $204.05 | 2019-2024 | Monjuvi, Pemazyre, Jakafi |
| Eisai INC. | $188.11 | 2019-2024 | |
| Lilly USA, LLC | $187.47 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $163.75 | 2019-2024 | |
| Daiichi Sankyo INC. | $149.78 | 2019-2024 | Enhertu, Injectafer |
| Array Biopharma INC | $147.23 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Glaxosmithkline, LLC. | $145.41 | 2023-2024 | Ojjaara, Jemperli |
| Exelixis INC. | $139.72 | 2019-2024 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $136.94 | 2019-2024 | Tavalisse, Rezlidhia |
| Regeneron Healthcare Solutions, INC. | $136.11 | 2023-2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $128.39 | 2023-2024 | Fotivda |
| Astellas Pharma US INC | $121.91 | 2023-2024 | Xospata, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $120.56 | 2019-2023 | Vonvendi, Ninlaro, Alunbrig |
| Coherus Oncology, INC. | $99.13 | 2023-2024 | |
| Sobi, INC | $93.78 | 2023-2024 | |
| Amgen INC. | $92.45 | 2019-2023 | Lumakras, Kyprolis |
| Kite Pharma, INC. | $79.99 | 2022-2023 | Yescarta |
| Puma Biotechnology, INC. | $69.19 | 2019-2024 | |
| Stemline Therapeutics INC. | $66.12 | 2023-2024 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $63.20 | 2019-2024 | Onivyde |
| Pharmaessentia USA Corporation | $62.50 | 2022-2024 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $50.42 | 2019-2023 | |
| Karyopharm Therapeutics INC. | $47.93 | 2023-2024 | Xpovio |
| Myriad Genetic Laboratories, INC. | $47.12 | 2023-2024 | Myrisk, Precisetumor |
| Alexion Pharmaceuticals, INC. | $46.84 | 2019-2024 | Ultomiris |
| Adc Therapeutics America, INC. | $42.68 | 2023-2024 | |
| Progenics Pharmaceuticals, INC. | $41.93 | 2023-2024 | Pylarify |
| Servier Pharmaceuticals LLC | $38.19 | 2024 | |
| Sirtex Medical INC | $32.44 | 2019 | |
| Emd Serono, INC. | $31.20 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $28.56 | 2024 | Orgovyx |
| Morphosys, US INC. | $28.11 | 2022-2023 | Monjuvi |
| Deciphera Pharmaceuticals INC. | $24.30 | 2024 | Qinlock |
| Apellis Pharmaceuticals, INC. | $21.03 | 2023 | Empaveli |
| Amag Pharmaceuticals, INC. | $17.79 | 2019 | |
| Novocure INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Rella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.